Precision Oncology Clinical Diagnostic Study In Primary and Metastatic Breast Cancer (PRISM)
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This study aims to provide information about the genomics of your breast cancer which your oncologist can use to enhance the treatment of your disease possibly enabling more targeted and personalised therapy.This study will carry out TruSight Oncology Comprehensive (TSOComprehensive) testing on breast cancer tumour tissue that was collected at the time of your breast cancer diagnosis or during your breast surgery or if you have brain metastasis and you have had a biopsy for this. The TruSight Oncology Comprehensive assay is a next-generation sequencing (NGS) test used to analyse cancer-related genomic changes in patients, offering a comprehensive view of potential mutations and other alterations that can impact treatment decisions. The TruSight Oncology Comprehensive assay is CE-IVD marked for use in Europe, meaning that it complies with the relevant EU regulation, for comprehensive genomic profiling for different types of cancer. It analyses 523 cancer-relevant genes from both DNA and RNA to identify variations. It will also look for changes and mutations which may affect cell growth and stability. By identifying relevant mutations and biomarkers, the assay can help oncologists select the most appropriate treatment strategies with the aim of improving patient outcomes.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Pacjentki z rakiem piersi, u których pobrano lub usunięto guz.
- •Pacjentki z przerzutami raka piersi do mózgu, u których pobrano próbkę guza.
- •Pacjentki, które otrzymały leczenie przed operacją (jeśli dotyczy).
- •Pacjentki powyżej 18 roku życia.
- •Pacjentki, które mogą wyrazić świadomą zgodę na udział w badaniu.
✗ Disqualifies
- •Pacjentki bez potwierdzonego raka piersi.
- •Pacjentki, których stan zdrowia może utrudnić udział w badaniu według oceny lekarza.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- February 20, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (3)
Beaumont RCSI Cancer Centre
Dublin, Ireland
Cork University Hospital
Cork, Ireland
University Hospital Galway
Galway, Ireland
Trial contact
Cancer Trials Ireland
Leonie Young
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.